Definitive Contract 75F40120C00069
Award Date
8/26/20
Potential Completion Date
9/28/23
Potential Value
$696K
Federal Agency
Food and Drug Administration
Awardee
Duke University
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27708, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $699,087.00, was issued by the Food and Drug Administration (FDA) to Duke University's Office of Research Administration Division. The contract is a definitive Firm Fixed Price contract with a period of performance through March 12, 2028. It was awarded under a Broad Agency Announcement (BAA) that solicits research and development proposals to support the FDA's regulatory science and innovation agenda. Duke University, a leading academic research...
Duke University Office of Research Administration Division was awarded a $274,413 definitive contract by the Department of Health and Human Services Food and Drug Administration to conduct a study using electronic health records to identify and assess adverse events for biologic therapies. The contract aims to develop and validate methodological approaches under the agency's Broad Agency Announcement for the Advanced Research and Development of Regulatory Science, which seeks proposals to...
The U.S. Food and Drug Administration (FDA) has awarded a $1,567,108.00 definitive cost-no-fee contract to Duke University to conduct a study on Medicare Advantage for real-world evidence in cardiovascular disease. The contract has an ultimate completion date of September 29, 2026. Duke University, a prominent private research university, will be the prime contractor for this effort, which is not set aside under any special program. The contract award indicates Duke University's extensive...
This federal contract was awarded to Duke University by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to support the development and deployment of COVID-19 vaccines under Operation Warp Speed. The $281,376.08 definitive cost-no-fee contract, awarded on September 17, 2021, does not have a set-aside designation. The contract supports research and development activities to advance regulatory science and innovation, which aligns with Duke University's expertise...
Duke University has been awarded a firm fixed price purchase order totaling $22,137 by the Department of Health and Human Services Food and Drug Administration. The contract is for technical expertise in predictive toxicology for drug-induced liver injury to be delivered through April 2025 in Durham, North Carolina. As the prime contractor, Duke University will provide technical expert services through its Office of Research Administration to support the FDA's predictive toxicology programs....
The Department of Health and Human Services Food and Drug Administration awarded a definitive cost-no-fee contract to Duke University Office of Research Administration Division for the "Evaluating Fitness-for-Use of Electronic Health Records in Clinical Research" project. The contract has a potential value of $1,269,675.26 and a completion date of December 30, 2022. This contract is not set aside. As the prime contractor, Duke University will provide clinical research and...
The U.S. Food and Drug Administration (FDA) awarded a $400,000.00 firm-fixed price contract to the Regents of the University of Michigan, Office of Research and Sponsored Projects (University of Michigan) to advance the science of in vitro, animal model, pharmacokinetic studies, and/or real-world evidence studies to facilitate drug development, including studies focused on antimicrobial resistance and drug development. This contract has a period of performance through March 31, 2026. The...
Duke University is the prime contractor on a $1,609,333 cost-no-fee definitive contract with the Department of Health and Human Services' Food and Drug Administration to perform research titled "Quantifying Patients' Benefit-Risk Tradeoffs Associated with Percutaneous Revascularization Options for Peripheral Arterial Disease: A Collaborative Effort with the Rapid Pathways Patient Science Working Group." There is no set-aside designation. Major subcontractors include the University of...
This is a $629,799.52 federal contract awarded by the Food and Drug Administration (FDA) to Duke University, a private university and non-profit organization. The contract is for a project titled "Bridging Novel Laboratory Animal and Hollow Fiber Infection Models to Evaluate Central Nervous System Penetration of Drugs in Infants." The contract is a definitive contract with a cost-no-fee pricing type and has an ultimate completion date of September 29, 2020. There was no set-aside...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $21,750 purchase order to Howard University for research services. The firm fixed price contract has a period of performance from April 2017 to April 2019. As the prime contractor, Howard University will perform the research services out of its division located in Silver Spring, Maryland. No additional details were provided regarding the scope of work, but the FDA funds various clinical trials and...